Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11907130 | 0.86 | PARP1 (0.51) | PARP1JAK2HTTHPGDALDH1A1 | |
| SCHEMBL254490 | 0.74 | HRH3 (0.72) | HRH3HDAC1HTTHIF1AEPAS1 | |
| SCHEMBL16416563 | 0.74 | PARP1 (1.00) | PARP1HRH3HDAC1JAK2 | |
| SCHEMBL27646067 | 0.74 | HRH3 (0.54) | PARP1HRH3KCNJ1HTTAOC3 | |
| SCHEMBL3721164 | 0.74 | PARP1 (0.47) | PARP1HRH3JAK2 | |
| SCHEMBL145531 | 0.73 | ALDH1A1 (0.54) | HRH3KCNJ1HTTAOC3HIF1A | |
| SCHEMBL11908303 | 0.72 | MAP2K3 (0.73) | PARP1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL426993 | 0.72 | HPGD (0.66) | HRH3HTTHIF1AEPAS1HPGD | |
| SCHEMBL11908374 | 0.72 | MAP2K3 (0.77) | PARP1ALDH1A1MAPTSMN1; SMN2MAP2K3 | |
| SCHEMBL16054714 | 0.72 | HRH3 (0.72) | HRH3HDAC1KCNJ1JAK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PARP1 949/4885HRH3 4473/4885ACVR1 2513/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PARP1 949/4885HRH3 4473/4885ACVR1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.